EMA highlights link between hydroxychloroquine and psychiatric disorders
The EMA recommends updating the product information for chloroquine and hydroxychloroquine after confirming a link between these medicines and psychiatric disorders.
List view / Grid view
News
UK secures total of 357 million doses of various COVID-19 vaccines
After purchasing an additional two million doses of Moderna's COVID-19 vaccine, the UK will now receive a total of 357 million doses of vaccines from seven developers.
WHO report suggests African countries are not ready for COVID-19 vaccines
The WHO Regional Director for Africa urges governments to “ramp up readiness” as report suggests the region is not prepared for a COVID-19 vaccine roll-out.
EU secures 80 million doses of Moderna COVID-19 vaccine
The European Commission and Moderna have agreed that the company will supply at least 80 million doses of mRNA-1273, the company's COVID-19 vaccine candidate.
COVAXX commits to deliver 140 million COVID-19 vaccine doses to emerging markets
The company suggests their experimental COVID-19 vaccine, UB-612, has the features and potential to disrupt the traditional vaccine distribution and supply status quo.
EC fines Teva and Cephalon €60.5 million over pay-for-delay deal
The European Commission has fined Teva and Cephalon €60.5 million for a pay-for-delay deal over Cephalon's modafinil and Teva's generic.
EDQM releases updated pharmacopoeial quality standards for vaccines
To aid COVID-19 vaccine developers, the EDQM has released an updated European Pharmacopoeia that can be accessed for free.
EC announces new Pharmaceutical Strategy for Europe
The strategy outlines actions to strengthen EU supply chains, encourage innovation and ensure medicines are affordable and sustainable.
Trial to compare dexamethasone and baricitinib in hospitalised COVID-19 patients
The fourth iteration of the COVID-19 treatment trial will determine whether remdesivir plus baricitinib or dexamethasone is more effective at promoting recovery from COVID-19.
Phase II trial to study anti-COVID-19 mAb CT-P59 completes enrolment
A trial of CT-P59, an anti-COVID-19 monoclonal antibody, has completed its enrolment and will study the treatment against standard-of-care.
British pharma responds to UK’s Chancellor’s new Spending Review
The ABPI has commented on the new Spending Review and outlined ways the UK government can help the life sciences sector.
EC approves Opdivo for treatment of oesophageal squamous cell carcinoma
The European Commission has approved Opdivo (nivolumab) to treat oesophageal squamous cell carcinoma after studies showed its clinical benefits compared to chemotherapy alone.
One of the oldest vaccines could help combat COVID-19
Researchers have shown that recipients of the Bacillus Calmette-Guérin (BCG) vaccine are less likely to contract COVID-19 in a new study.
New microneedle vaccine shows promise in pre-clinical trials
A single-use, self-administered microneedle vaccine has been developed to provide immunisation against infectious diseases.
EC approves new meningitis vaccine
MenQuadfi® has been approved for use in individuals 12 months of age and older, based on its safety and immunogenicity in 6,300 trial subjects.
